Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Despite broad approvals based on intent-to-treat populations, adjuvant immune checkpoint inhibitors have shown hazard ratios above 1.0 for both disease-free and overall survival in upper tract subsets across trials like CheckMate 274 (HR 1.23) and IMvigor010. Consequently, oncologists hesitate to extrapolate bladder cancer trial outcomes to upper tract disease, as dedicated evidence demonstrating a therapeutic benefit in this anatomical subgroup remains absent.

Related Insights

Clinicians must weigh the immediate benefits of adding a PD-1 inhibitor for non-muscle-invasive bladder cancer against the potential loss of efficacy for crucial systemic therapies like EV-pembro if the disease later becomes metastatic. This introduces a new layer of long-term treatment strategy from the first diagnosis.

While adding PD-1 inhibitors to standard BCG therapy in high-risk non-muscle-invasive bladder cancer improves event-free survival, it also introduces significant Grade 3 toxicity (around 24%) without mature overall survival data, making its risk-benefit profile questionable.

Even though CheckMate 274 showed improved disease-free survival in PD-L1-positive patients overall, oncologists caution against relying on PD-L1 to prescribe adjuvant nivolumab for upper tract tumors. Across urothelial cancer trials—including frontline metastatic settings—the PD-L1 biomarker has repeatedly failed to predict outcomes reliably. Furthermore, regulatory labels do not mandate PD-L1 testing, making it an unreliable surrogate for overcoming negative upper tract checkpoint inhibitor performance.

In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.

Using a PD-1 inhibitor upfront with BCG for non-muscle-invasive bladder cancer is not an isolated decision. It creates a significant strategic challenge: this early exposure may compromise the efficacy of crucial systemic immunotherapies, like EV-Pembro, if the disease later progresses to a metastatic stage, forcing difficult long-term planning.

Current bladder cancer trials often fail to differentiate between patients with primary resistance (never responded) versus acquired resistance (responded, then progressed). Adopting this distinction, common in lung cancer research, could help identify patient subgroups more likely to benefit from immunotherapy re-challenge and refine trial eligibility criteria.

An expert argues forcefully that the PD-L1 biomarker should be "ditched" in bladder cancer. Citing its repeated failure to predict overall survival benefit across multiple major trials, it is deemed an oversimplified and unreliable tool that leads to both over- and under-treatment of patients.

Experts caution against making definitive clinical decisions based on subgroup analyses, such as the apparent lack of benefit for upper tract disease in an adjuvant immunotherapy trial. These analyses are hypothesis-generating, and conflicting results between different endpoints (e.g., DFS vs. OS) demonstrate they can be misleading.

In high-risk non-muscle invasive bladder cancer (NMIBC), trials like CREST and POTOMAC show adding a systemic immune checkpoint inhibitor to BCG therapy introduces significant toxicity. The benefit is primarily in local control, which may not justify the risk, especially with other effective intravesical options available.

Despite data from kidney cancer showing immunotherapy re-challenge is often ineffective, oncologists admit to using it in urothelial cancer. This highlights a clinical conflict where the desire to use a powerful drug class outweighs the lack of supporting evidence, especially in specific, confusing patient scenarios.